Aspirin intake and breast cancer survival – a nation-wide study using prospectively recorded data in Sweden

BMC Cancer

Karin Ekström Smedby¹  Johan Askling¹  Hans-Olov Adami²  Therese M-L Andersson²  Cecilia Lundholm²  Johanna Holm²  Yudi Pawitan²  Henrik Olsson²  Michelle D Holmes³ 

[1]Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

[2]Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

[3]Department of Epidemiology, Harvard School of Public Health, Boston, MA, US

关键词: Registries;    Sweden;    Prospective study;    Survival;    Breast neoplasms;    Aspirin;   

Others  :  858752
DOI  :  10.1186/1471-2407-14-391

 received in 2013-09-09, accepted in 2014-05-20,  发布年份 2014

【 摘 要 】

Background

Aspirin (ASA) use has been associated with improved breast cancer survival in several prospective studies.

Methods

We conducted a nested case–control study of ASA use after a breast cancer diagnosis among women using Swedish National Registries. We assessed prospectively recorded ASA exposure during several different time windows following cancer diagnosis using conditional logistic regression with breast cancer death as the main outcome. Within each six-month period of follow-up, we categorized dispensed ASA doses into three groups: 0, less than 1, and 1 or more daily doses.

Results

We included 27,426 women diagnosed with breast cancer between 2005 and 2009; 1,661 died of breast cancer when followed until Dec 31, 2010. There was no association between ASA use and breast cancer death when exposure was assessed either shortly after diagnosis, or 3–12 months before the end of follow-up. Only during the period 0–6 months before the end of follow-up was ASA use at least daily compared with non-use associated with a decreased risk of breast cancer death: HR (95% CI) = 0.69 (0.56-0.86). However, in the same time-frame, those using ASA less than daily had an increased risk of breast cancer death: HR (95% CI) = 1.43 (1.09-1.87).

Conclusions

Contrary to other studies, we did not find that ASA use was associated with a lower risk of death from breast cancer, except when assessed short term with no delay to death/end of follow-up, which may reflect discontinuation of ASA during terminal illness.

【 授权许可】

   
2014 Holmes et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN: Is breast cancer survival improving? Cancer 2004, 100(1):44-52.
• [2]Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351(27):2817-2826.
• [3]Breast cancer in developing countries Lancet 2009, 374(9701):1567. doi:10.1016/S0140-6736(09)61930-9
• [4]Holmes MD, Chen WY: Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality. Breast Cancer Res 2012, 14(2):216. BioMed Central Full Text
• [5]Statistics Sweden: Background Facts, Labour and Education Statistics 2009:1, Integrated database for labour market research. Statistics Sweden; 2009.
• [6]Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundstrom A, Westerholm B, Rosen M: The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007, 16(7):726-735.
• [7]Hansson LE, Nyren O, Hsing AW, Bergstrom R, Josefsson S, Chow WH, Fraumeni JF Jr, Adami HO: The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996, 335(4):242-249.
• [8]Kim RS: Lesser known facts about nested case–control designs. J Transl Med Epidemiol 2013, 1(1):1007.
• [9]Kwan ML, Habel LA, Slattery ML, Caan B: NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 2007, 18(6):613-620.
• [10]Blair CK, Sweeney C, Anderson KE, Folsom AR: NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 2007, 101(2):191-197.
• [11]Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE: Aspirin intake and survival after breast cancer. J Clin Oncol 2010, 28(9):1467-1472. doi:10.1200/JCO.2009.22.7918. Epub 2010 Feb 16. PMID: 20159825
• [12]Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z: Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379(9826):1591-1601.
• [13]Algra AM, Rothwell PM: Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012, 13(5):518-527. doi:10.1016/S1470-2045(12)70112-2. Epub 2012 Mar 21. Review. PMID: 22440112.
• [14]Pharmaceuticals - Statistics for 2009 http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18278/2011-3-30.pdf webcite
• [15]Li Y, Brasky TM, Nie J, Ambrosone CB, McCann SE, Shields PG, Trevisan M, Edge SB, Freudenheim JL: Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2012, 21(1):239-242.
• [16]Cheng L, Swartz MD, Zhao H, Kapadia AS, Lai D, Rowan PJ, Buchholz TA, Giordano SH: Hazard of recurrence among women after primary breast cancer treatment–a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev 2012, 21(5):800-809.